Abstract:Positive allosteric modulators (PAMs) of the cannabinoid CB1 receptor (CB1) offer potential therapeutic advantages in the treatment of neuropathic pain and addiction by avoiding the adverse effects associated with orthosteric CB1 activation. Here, molecular modeling and mutagenesis were used to identify residues central to PAM activity at CB1. Six putative allosteric binding sites were identified in silico, including novel sites previously associated with cholesterol binding, and key residues within each site were mutated to alanine. The recently determined ZCZ011 binding site was found to be essential for allosteric agonism, as GAT228, GAT229 and ZCZ011 all increased wild-type G protein dissociation in the absence of an orthosteric ligand; activity that was abolished in mutants F191A3.27 and I169A2.56. PAM activity was demonstrated for ZCZ011 in the presence of the orthosteric ligand CP55940, which was only abolished in I169A2.56. In contrast, the PAM activity of GAT229 was reduced for mutants R220A3.56, L404A8.50, F191A3.27 and I169A2.56. This indicates that allosteric modulation may represent the net effect of binding at multiple sites, and that allosteric agonism is likely to be mediated via the ZCZ011 site. This study underlines the need for detailed understanding of ligand receptor interactions in the search for pure CB1 allosteric modulators.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to determine the positive allosteric modulator (PAM) binding sites of the cannabinoid CB1 receptor, in order to better understand its mechanism of action and provide a basis for the development of new drugs. Specifically, the study uses mutational analysis to identify residues that are crucial for PAM activity, especially those key sites that bind to compounds such as ZCZ011, GAT228 and GAT229. ### Research Background The cannabinoid CB1 receptor (CB1) is the most abundant G - protein - coupled receptor (GPCR) in the brain and plays an important role in the regulation of neurotransmitter release. Classical CB1 activation leads to a series of physiological effects, but is also accompanied by adverse reactions, such as catalepsy, tolerance and dependence. Therefore, researchers have turned to the study of allosteric modulators, hoping to find new therapies that can avoid these adverse reactions. ### Research Methods To determine the positive allosteric modulator binding sites on the CB1 receptor, the researchers used the methods of molecular modeling and mutational analysis. They first identified six potential allosteric binding sites through computer simulation and selected several key residues at each site for mutation to alanine. These mutants were then used in experiments to evaluate their impact on CB1 receptor function. ### Main Findings 1. **Importance of the ZCZ011 binding site**: The study shows that the ZCZ011 binding site is crucial for allosteric agonism. The F191A3.27 and I169A2.56 mutants significantly reduce the allosteric agonistic activity of ZCZ011. 2. **Role of multiple binding sites**: The study also shows that allosteric regulation may be the result of the combined action of multiple binding sites. For example, the allosteric regulatory activity of GAT229 is weakened in the R220A3.56, L404A8.50, F191A3.27 and I169A2.56 mutants. 3. **Potential influence of cholesterol binding sites**: The study has discovered two new cholesterol binding sites (Site 5 and Site 5.5), which suggests that cholesterol may play a certain role in the allosteric regulation of the CB1 receptor. ### Conclusion This study has analyzed in detail the binding sites of positive allosteric modulators on the CB1 receptor through mutational analysis, providing an important basis for further designing new drugs with specific effects. At the same time, the study also emphasizes the importance of in - depth understanding of ligand - receptor interactions, especially in the search for pure CB1 allosteric modulators. ### Key Formulas This article does not involve complex mathematical or physical formulas, and mainly uses experimental data and statistical analysis to support the conclusions.

Determination of the Cannabinoid CB1 Receptor's Positive Allosteric Modulator Binding Site through Mutagenesis Studies

Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1

Positive allosteric modulation of the cannabinoid CB1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects (adv. Sci. 17/2021)

Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface

Structure of an allosteric modulator bound to the CB1 cannabinoid receptor

Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor

Allosteric Modulation of Cannabinoid Receptor 1—Current Challenges and Future Opportunities

In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor

Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1

The future of type 1 cannabinoid receptor allosteric ligands

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Abstract P2154: A Novel Allosteric Modulator of the Β 1 AR Identified by DNA-encoded Small Molecule Library Screening Demonstrates Unique Pharmacology and Function

Exploring the Putative Mechanism of Allosteric Modulations by Mixed-Action Kappa/mu Opioid Receptor Bitopic Modulators.

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Structure-Activity Relationships and Molecular Pharmacology of Positive Allosteric Modulators of the Mu-Opioid Receptor

Computational Insights into the Molecular Mechanisms of Differentiated Allosteric Modulation at the Mu Opioid Receptor by Structurally Similar Bitopic Modulators

Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor

Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs

Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function

Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors